Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Maria Sainz Biography and Net Worth

Director of Shockwave Medical

Maria is the former President and CEO of AEGEA Medical Inc., a women’s health technology company acquired by CooperSurgical in 2021. She serves as a member of the Board of Directors of ShockWave Medical, Inc., Avanos Medical, Inc., and Atrion Corporation. Ms. Sainz brings more than 20 years of experience leading large medical device companies and medtech start-ups.

What is Maria Sainz's net worth?: The estimated net worth of Maria Sainz is at least $1.51 million as of February 23rd, 2023. Mr. Sainz owns 4,592 shares of Shockwave Medical stock worth more than $1,510,768 as of April 20th. This net worth estimate does not reflect any other assets that Mr. Sainz may own. Learn More about Maria Sainz's net worth.
How do I contact Maria Sainz?: The corporate mailing address for Mr. Sainz and other Shockwave Medical executives is 5403 Betsy Ross Drive, Santa Clara CA, 95054. Shockwave Medical can also be reached via phone at (877) 775-4846 and via email at [email protected]. Learn More on Maria Sainz's contact information.
Has Maria Sainz been buying or selling shares of Shockwave Medical?: Maria Sainz has not been actively trading shares of Shockwave Medical within the last three months. Most recently, Maria Sainz sold 724 shares of the business's stock in a transaction on Thursday, February 23rd. The shares were sold at an average price of $193.00, for a transaction totalling $139,732.00. Following the completion of the sale, the director now directly owns 4,592 shares of the company's stock, valued at $886,256. Learn More on Maria Sainz's trading history.
Who are Shockwave Medical's active insiders?: Shockwave Medical's insider roster includes Colin Cahill (Director), Laura Francis (Director), Douglas Godshall (CEO), Antoine Papiernik (Director), Trinh Phung (VP), Dan Puckett (CFO), Maria Sainz (Director), Frank Watkins (Director), and Isaac Zacharias (Insider). Learn More on Shockwave Medical's active insiders.
Are insiders buying or selling shares of Shockwave Medical?: In the last year, insiders at the sold shares 45 times. They sold a total of 220,491 shares worth more than $51,852,379.53. The most recent insider tranaction occured on March, 26th when Director Laura Francis sold 1,500 shares worth more than $450,000.00. Insiders at Shockwave Medical own 3.4% of the company. Learn More about insider trades at Shockwave Medical.
Information on this page was last updated on 3/26/2024.

Maria Sainz Insider Trading History at Shockwave Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/23/2023	Sell	724	$193.00	$139,732.00	4,592
9/8/2022	Sell	650	$295.00	$191,750.00	5,316

Maria Sainz Buying and Selling Activity at Shockwave Medical

Shockwave Medical Company Overview

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Today's Range

Now: $329.00

$327.39

$329.80

50 Day Range

MA: $284.02

$230.90

$329.64

2 Week Range

Now: $329.00

$157.00

$331.58

Volume

1,302,713 shs

Average Volume

963,086 shs

Market Capitalization

$12.30 billion

P/E Ratio

85.01

Dividend Yield

N/A

Beta

0.92